NCT05725720Active, not recruiting
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
Despite impressive outcomes in selected patients, significant heterogeneity in clinical response to CAR-T cell therapy remains. The gut microbiome (GM) has recently emerged as one of the key modifiable factors of prognosis and response to treatment in cancer patients, with high-diversity profiles rich in health-associated taxa while poor in pathobionts generally associated with better response and longer survival. Currently, it is unknown if GM also modulates anti-tumor responses to CAR-T cells and related toxicities in lymphomas.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 69 (actual)
- First submitted
- 31 Jan 2023
- Start date
- 23 Mar 2023
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- University of Bologna
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT05725720
What you commit to
- Study type: Observational
- Participants enrolled: 69
- From 23 Mar 2023 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
- Concurrent second malignancy.
Who the study is looking for
- Age ≥18 years.
- Patients affected by histologically confirmed DLBCL.
- Patients amenable for CAR-T cell therapy as for clinical approved indication (commercial products).
- Patients must provide written informed consent.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute Of Hematology "Seràgnoli" Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.